Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)
- PMID: 28295985
- DOI: 10.1002/ejhf.798
Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)
Abstract
Aims: While the conditions of heart failure (HF) with reduced (HFrEF, LVEF < 40%) and preserved (HFpEF, LVEF ≥ 50%) left ventricular ejection fraction (LVEF) are well characterized, it is unknown whether patients with HF and mid-range LVEF (HFmrEF, LVEF 40-49%) have to be regarded as a separate clinical entity. The aim of this study was to characterize these three populations and to compare outcome and response to therapy.
Methods and results: The analysis was based on the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) comprising a population with established HF including the whole spectrum of LVEF. Of the 622 patients, 108 (17%) were classified as having HFmrEF. This group was in general found to be 'intermediate' regarding clinical characteristics with a comparable and high burden of comorbidities and equally impaired quality of life but was more likely to have coronary artery disease as compared with the HFpEF group. During a median follow-up of 794 days, mortality was 39.7% without significant differences between groups. N-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided as compared with standard therapy resulted in improved survival free of HF hospitalizations in HFrEF and HFmrEF, but not in HFpEF.
Conclusion: Although the 'intermediate' clinical profile of HFmrEF between HFrEF and HFpEF would support the conclusion that HFmrEF is a distinct clinical entity, we hypothesize that HFmrEF has to be categorized as HFrEF because of the high prevalence of coronary artery disease and the similar benefit of NT-proBNP-guided therapy in HFrEF and HFmrEF, in contrast to HFpEF.
Keywords: Heart failure; Heart failure with mid-range ejection fraction; Heart failure with preserved ejection fraction; Heart failure with reduced ejection fraction; Prognosis.
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.
Similar articles
-
Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.Clin Res Cardiol. 2017 May;106(5):359-368. doi: 10.1007/s00392-016-1063-0. Epub 2016 Dec 20. Clin Res Cardiol. 2017. PMID: 27999929
-
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).Eur J Heart Fail. 2013 Oct;15(10):1148-56. doi: 10.1093/eurjhf/hft076. Epub 2013 May 8. Eur J Heart Fail. 2013. PMID: 23657728 Clinical Trial.
-
Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.Eur J Heart Fail. 2017 Oct;19(10):1258-1269. doi: 10.1002/ejhf.807. Epub 2017 Mar 31. Eur J Heart Fail. 2017. PMID: 28370829
-
Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions.JACC Heart Fail. 2017 Nov;5(11):763-771. doi: 10.1016/j.jchf.2017.06.013. Epub 2017 Oct 11. JACC Heart Fail. 2017. PMID: 29032140 Free PMC article. Review.
-
Left ventricular ejection fraction as therapeutic target: is it the ideal marker?Heart Fail Rev. 2017 Nov;22(6):641-655. doi: 10.1007/s10741-017-9624-5. Heart Fail Rev. 2017. PMID: 28601914 Review.
Cited by
-
Association of Prior Left Ventricular Ejection Fraction With Clinical Outcomes in Patients With Heart Failure With Midrange Ejection Fraction.JAMA Cardiol. 2020 Sep 1;5(9):1027-1035. doi: 10.1001/jamacardio.2020.2081. JAMA Cardiol. 2020. PMID: 32936274 Free PMC article.
-
Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China.BMC Cardiovasc Disord. 2019 Sep 2;19(1):209. doi: 10.1186/s12872-019-1177-1. BMC Cardiovasc Disord. 2019. PMID: 31477021 Free PMC article.
-
Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines.ESC Heart Fail. 2020 Apr;7(2):381-399. doi: 10.1002/ehf2.12586. Epub 2020 Apr 1. ESC Heart Fail. 2020. PMID: 32239646 Free PMC article. Review.
-
Beta-blockers are associated with reverse remodeling in patients with dilated cardiomyopathy and mid-range ejection fraction.Am Heart J Plus. 2021 Oct 7;11:100053. doi: 10.1016/j.ahjo.2021.100053. eCollection 2021 Nov. Am Heart J Plus. 2021. PMID: 38559320 Free PMC article.
-
Web-Based Dynamic Nomogram for Predicting Risk of Mortality in Heart Failure with Mildly Reduced Ejection Fraction.Risk Manag Healthc Policy. 2024 Aug 13;17:1959-1972. doi: 10.2147/RMHP.S474862. eCollection 2024. Risk Manag Healthc Policy. 2024. PMID: 39156077 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous